Skip to main content
. 2022 Nov 5;12:18777. doi: 10.1038/s41598-022-23607-w

Table 2.

Hazard ratios and 95% confidence intervals for development of exudative age-related macular degeneration according to baseline lipid profile.

Subject No Case No Duration (person-years) IR per 100,000 person-years Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI)
Overall 6,129,616 18,803 29,961,137 62.76
Baseline total cholesterol
Q1 (lowest) 1,524,313 5,970 7,352,593 81.20 1.00 (reference) 1.00 (reference) 1.00 (reference)
Q2 1,496,337 4,702 7,327,003 64.17 0.95 (0.91–0.98) 1.00 (0.96–1.04) 1.00 (0.96–1.04)
Q3 1,549,911 4,373 7,615,387 57.42 0.94 (0.90–0.97) 1.01 (0.97–1.05) 1.01 (0.97–1.05)
Q4 (highest) 1,559,055 3,758 7,666,154 49.02 0.90 (0.86–0.94) 0.98 (0.94–1.02) 0.97 (0.93–1.01)
Baseline HDL cholesterol
Q1 (lowest) 1,450,022 5,056 7,048,349 71.73 1.00 (reference) 1.00 (reference) 1.00 (reference)
Q2 1,524,625 4,859 7,465,328 65.09 1.03 (0.99–1.08) 1.05 (1.01–1.09) 1.06 (1.02–1.10)
Q3 1,614,880 4,730 7,914,017 59.77 1.03 (0.99–1.08) 1.06 (1.01–1.10) 1.07 (1.03–1.12)
Q4 (highest) 1,540,089 4,158 7,533,444 55.19 1.07 (1.03–1.12) 1.11 (1.06–1.15) 1.13 (1.08–1.18)
Baseline LDL cholesterol
Q1 (lowest) 1,517,736 5,662 7,339,297 77.15 1.00 (reference) 1.00 (reference) 1.00 (reference)
Q2 1,547,973 4,915 7,569,841 64.93 0.96 (0.93–1.00) 1.03 (0.99–1.07) 1.03 (0.99–1.07)
Q3 1,493,483 4,266 7,330,769 58.19 0.93 (0.90–0.97) 1.02 (0.98–1.06) 1.02 (0.98–1.06)
Q4 (highest) 1,570,424 3,960 7,721,230 51.29 0.91 (0.88–0.95) 1.01 (0.96–1.05) 1.00 (0.96–1.04)
Baseline TG
Q1 (lowest) 1,503,719 4,583 7,333,871 62.49 1.00 (reference) 1.00 (reference) 1.00 (reference)
Q2 1,548,052 4,910 7,555,056 64.99 0.97 (0.93–1.01) 0.96 (0.92–1.00) 0.94 (0.91–0.98)
Q3 1,532,448 4,925 7,493,265 65.73 0.97 (0.94–1.01) 0.95 (0.91–0.99) 0.93 (0.89–0.97)
Q4 (highest) 1,545,397 4,385 7,578,945 57.86 0.90 (0.86–0.93) 0.87 (0.83–0.90) 0.84 (0.81–0.88)

IR incidence rate, HR hazard ratio, CI confidence interval, Q quartile, HDL high-density lipoprotein, LDL low-density lipoprotein, TG triglycerides.

Model 1: adjusted for age and sex.

Model 2: adjusted for demographic factors (age, sex, income level), and systemic comorbidities (hypertension, diabetes mellitus, stroke, heart disease, chronic kidney disease, and dyslipidemia medication).

Model 3: adjusted for demographic factors, systemic comorbidities, and behavioral factors (smoking history, drinking habits, physical activity, and body mass index).